VIVUS, Inc. (Nasdaq: VVUS) today announced that phase 3 data on avanafil, a next generation oral phosphodiesterase type 5 (PDE5) inhibitor therapy being investigated for the treatment of erectile dysfunction (ED), will be presented next Tuesday at the American Urological Association (AUA) 2010 Annual Meeting in San Francisco, California. Irwin Goldstein, M.D., clinical professor of surgery at the University of California, San Diego, and director of sexual medicine at Alvarado Hospital in San Diego, will deliver an oral presentation as part of the Late-Breaking Science Forum session on Tuesday, June 1 entitled: "Avanafil for the Treatment of Erectile Dysfunction: Results of a Phase 3, Multi-Center, Randomized, Double Blind, Placebo-Controlled Clinical Trial."
Dr Goldstein's presentation will include the results from the REVIVE (TA-301) study a randomized, double-blind, placebo-controlled phase 3 study of avanafil in 646 men with a history of generalized ED.
"The AUA annual meeting is an excellent clinical forum for presenting the initial phase 3 experience regarding the use of avanafil in men with erectile dysfunction. We are pleased to have Dr. Goldstein leading the first scientific presentation of these pivotal study results," stated Wesley Day, Ph.D., vice president, clinical development at VIVUS. "The market for oral ED therapies continues to grow with worldwide sales of approved oral PDE5 inhibitors expected to exceed $4 billion this year. With successful intercourse in 15 minutes, avanafil may be favorably positioned in this market. We believe that, if approved, avanafil will represent an advance in the treatment of ED, and we are pleased to have the opportunity to review these data with the urology community at this important clinical gathering."
Pregnancy vitamin D supplementation boosts bone density in kids up to age 7